Neuropace, Inc. NPCE Ratios & Valuation
| FY'25 | FY'24 | FY'23 | FY'22 | ||
|---|---|---|---|---|---|
| Profitability | |||||
| Gross margin | 77.2%+3.3pp | 73.9%+0.4pp | 73.6%+2.2pp | 71.4%-2.6pp | |
| Operating margin | -16.3%+10.8pp | -27.1%+14.4pp | -41.5%+48.1pp | -89.6%-37.1pp | |
| Net margin | -21.5%+12.5pp | -34%+16.4pp | -50.4%+53.1pp | -103.4%-23.6pp | |
| EBITDA margin | -16%+10.7pp | -26.8%+14.3pp | -41.1%+47.8pp | -88.9%-37.1pp | |
| Free cash flow margin | -11.7%+11.1pp | -22.8%+7.5pp | -30.4%+51.9pp | -82.3%-27.1pp | |
| Returns | |||||
| Return on equity | -158.7%+30.6pp | -189.4%-70.4pp | -118.9%-31.9pp | -87%— | |
| Return on assets | -21.4%+5.4pp | -26.8%+2.9pp | -29.7%+8.3pp | -38%+0.1pp | |
| Return on invested capital | -24.1%+6.3pp | -30.4%+1.1pp | -31.5%+7.5pp | -39%— | |
| Efficiency | |||||
| Asset turnover | 1×+0.2× | 0.8×+0.2× | 0.6×+0.2× | 0.4×-0.1× | |
| Inventory turnover | 1.5×-0.2× | 1.7×0.0× | 1.7×+0.2× | 1.5×-0.1× | |
| Liquidity | |||||
| Current ratio | 5.3×-0.1× | 5.4×-0.3× | 5.7×-3.2× | 8.9×-5.4× | |
| Quick ratio | 4.3×-0.2× | 4.5×-0.5× | 5×-3.0× | 8×-5.4× | |
| Cash ratio | 1.2×+0.3× | 0.9×-0.2× | 1.1×+0.5× | 0.6×-1.5× | |
| Leverage | |||||
| Debt-to-equity | 3.7×-5.4× | 9.2×+5.6× | 3.5×+1.5× | 2×+1.2× | |
| Debt-to-assets | 0.7×-0.1× | 0.8×+0.1× | 0.7×+0.1× | 0.6×+0.2× | |
| Interest coverage | -2.2×+0.3× | -2.5×+0.7× | -3.2×+2.2× | -5.4×-2.2× | |
| Per Share | |||||
| Book value per share | $0.58+111% | $0.28-65.6% | $0.80-43.5% | $1.41-68.0% | |
| Valuation | |||||
| Market capitalization | $557.77M+63.4% | $334M+20.9% | $276.3M+647% | $37M-84.9% | |
| Enterprise value | $612.6M+58.1% | $393.79M+19.1% | $330.52M+230% | $100.04M-64.7% | |
| Price / sales | 5.6×+1.6× | 4.2×0.0× | 4.2×+3.4× | 0.8×-4.6× | |
| Price / book | 38.6×+24.5× | 41.7×+28.3× | 13.4×+12.3× | 1.1×-2.3× | |
| EV / sales | 6.2×+1.6× | 4.9×-0.1× | 5.1×+2.9× | 2.2×-4.1× | |
| Free cash flow yield | -1.8%+3.5pp | -5.5%+1.7pp | -7.2%+94.1pp | -101.3%-91.1pp | |
| Earnings yield | -3.9%+3.4pp | -8.1%+3.8pp | -11.9%+115pp | -127.2%-113pp |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- What are Neuropace, Inc.'s profit margins?
- Neuropace, Inc. (NPCE) runs a 78.3% gross margin and a -16.8% operating margin, with a -21.7% net margin.
- Where do Neuropace, Inc.'s ratios come from?
- Every ratio is computed from Neuropace, Inc.'s SEC filings — trailing-twelve-month flows over period-end balances. Valuation multiples combine those fundamentals with market data, recomputed each period. Switch between quarterly, annual, and TTM, or open any ratio for its full history and peer comparisons.
